Ollin Biosciences bags $330M to push eye-disease therapy into Phase 3
Ollin Biosciences raised $330 million in a Series B to push its eye-disease therapy into Phase 3 trials for diabetic macular edema and wet age-related macular degeneration, with lead investors including TCGX and ARCH Venture Partners and participation from a pension fund and crossover investors, in one of biotech’s largest Series B rounds in years.